Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes
Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second...
September 2025
AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively “AusperBio”) announced that it has closed...
Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party
Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back...
Guangdong Taienkang Secures NMPA Approval for Safinamide Generic
Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA)...
Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its investigational injectable SHR‑1501...
GE Healthcare Eyes Sale of China Unit Amid Revenue Decline
GE Healthcare Technologies Inc. (NASDAQ: GEHC) is reportedly exploring the sale of a stake in...
Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...
GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China
Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC / OMX:...
Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products...
Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo
Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...
Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)...
Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open‑label, randomized Phase 3...
Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China
Eisai (TYO: 4523) China, operating through its subsidiary Eisai (Liaoning) Pharmaceutical Co., Ltd., announced a...
Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has filed a prospectus announcing plans to seek...
Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next‑generation small‑interfering RNA...
Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies
Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it will acquire 89bio, Inc. (NASDAQ: ETNB)...
Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes
A recent clinical study published by Eli Lilly & Co. (NYSE: LLY) demonstrates that the GLP‑1...
Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance
Siemens Healthineers (ETR: SHL) and Stryker (NYSE: SYK) today announced a strategic partnership to co‑develop...
China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs
The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...
Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal
Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund 3, L.P. to form Kalexo...